ÂÜÀòÂÒÂ×

David Brown, M.D. F.A.C.S. is the director of research at Retina Consultants of Texas, chair of the Medical Leadership Board of Retina Consultants of America (RCA), and a member of the RCA board of directors. Additionally, Dr. Brown is a Clinical Professor of Ophthalmology at Baylor College of Medicine, vice-chair for research for Houston Methodist Hospital, and is a member of NASA’s research and clinical advisory panel. Dr. Brown graduated from Baylor College of Medicine with highest honors and completed ophthalmology and retina training at the University of Iowa. He was a Thomas Heed Fellow, a Hermann Knapp Fellow, and was awarded the Ron Michels Fellowship award presented to the top retinal surgery fellow in the US in 1994.

Dr. Brown is a renowned leader in the retina and has published over 500 national meeting presentations, abstracts, and scientific papers, including many of the primary papers that established the use of anti-VEGF agents for AMD, retinal vein occlusion, and diabetic retinopathy (DR). He serves as a peer-reviewer for 8 ophthalmology journals and has authored 9 book chapters. Dr. Brown is an investigator in Ocuphire’s ZETA-1 Phase 2 clinical trial evaluating the safety and efficacy of oral APX3330 in patients with diabetic retinopathy.